Results 241 to 250 of about 115,232 (278)

Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. [PDF]

World J Exp Med
Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV.   +3 more
europepmc   +1 more source

A Humanized Anti‐gD Broadly Neutralizing Antibody Confers Complete Post‐Exposure Protection against Pseudorabies Virus

Advanced Science, EarlyView.
Pseudorabies virus (PRV), an emerging zoonotic α‐herpesvirus, causes life‐threatening human encephalitis. We identified a broad‐spectrum neutralizing antibody 6F7 targeting PRV gD. It blocks gD‐Nectin‐1 binding and membrane fusion, inhibiting replication across all PRV variants, representing a promising candidate for anti‐PRV therapy.
Yue Sun, Jianbo Liu, Shi‐Jia Xu, Meng‐Xin Wang, Hongliang Zhang, Yanhe Zhang, Zhi‐Jun Tian, Jin‐Mei Peng, Xin Yin, Tong‐Qing An, Xue‐Hui Cai, Yan‐Dong Tang   +11 more
wiley   +1 more source

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer. [PDF]

Radiology
O'Shea R, Horst C, Manickavasagar T, Josephides E, Hunter S, Taniere P, Nonaka D, Van Hemelrijck M, Spicer J, Hughes DJ, Cook GJR, Bille A, Karapanagiotou E, Goh V.   +13 more
europepmc   +1 more source

Bandgap‐Engineered PtxTey:Ag2Te Composite Quantum Dots Enable Programmable NIR‐II Imaging and Photothermal‐Immune Synergistic Therapy

Advanced Science, EarlyView.
A bandgap‐engineered PtxTey:Ag2Te quantum dot platform enables tunable NIR‐IIb emission for deep‐tissue imaging and mild photothermal therapy. Conjugation with αPD‐L1 confers dual tumor targeting and real‐time monitoring of PD‐L1 dynamics. Mild photothermal modulation induces immune reprogramming, enhancing checkpoint blockade efficacy and achieving ...
Jing Liu, Rui Xu, Quan Wu, Tian‐Xin Xiao, Lai‐Xi Zhao, Lei Sun, Ya‐Wen Zheng, Liang Dong, Zhi‐Quan Tian, Haibo Wang   +9 more
wiley   +1 more source

Severe Immune-related Adverse Events and Their Effect on Survival in Patients With Advanced Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. [PDF]

Cancer Diagn Progn
Nojiri T, Omura A, Nishimura H, Iede K, Takeyasu Y, Katsushima U, Higashiyama M.   +6 more
europepmc   +1 more source

PGK1 Suppresses CD8+ T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
PGK1 in tumor cells upregulates CCL2 expression through activation of the AKT/GSK‐3β/β‐catenin signaling axis, thereby promoting the recruitment and M2 polarization of TAMs and ultimately impairing the infiltration and activation of CD8+ T cells within the HCC tumor microenvironment. ABSTRACT Patients with advanced hepatocellular carcinoma (HCC) have a
Xi Liu, Jianpeng Liu, Zhihao Zhang, Xizhi Yu, Junjie Qian, Limin Ding, Qinchuan Wu, Zhe Yang, Xing‐Yu Luo, Xinjiang Ding, Rong Su, Xiaobo Yu, Yiting Qiao, Shengyong Yin, Haiyang Xie, Lin Zhou, Yuanxing Liu, Shusen Zheng   +17 more
wiley   +1 more source

A century of cell death research. [PDF]

J Cell Sci
Green DR.
europepmc   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

A Peptide Inhibitor of Lymphocyte Activation Gene-3 Interaction with Fibrinogen-like Protein 1 Synergizes with Programmed Death-Ligand 1 Blockade to Restore T Cell Activity and Inhibit Tumor Growth. [PDF]

Biomater Res
Lee SM, Gurung S, Park MS, Vadevoo SMP, Gunassekaran GR, Kim MJ, Kim SH, Kim HJ, Park EJ, Lee S, Im W, Kim S, Lee B.   +12 more
europepmc   +1 more source

Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol). [PDF]

Transl Lung Cancer Res
Huang S, Yang X, Zhao X, Kong Y, Zhang L, Xing P.   +5 more
europepmc   +1 more source